Start Over

The Parkinson's Disease Progression Neuroimaging Initiative.

Authors :: Zhu S
Ju Z
Wu P
Liu F
Ge J
Zhang H
Lu J
Li L
Wang M
Jiang J
Wang J
Zuo C
Source :: Behavioural neurology [Behav Neurol] 2021 Dec 30; Vol. 2021, pp. 2230196. Date of Electronic Publication: 2021 Dec 30 (Print Publication: 2021).
Publication Year :: 2021
Abstract: The Parkinson's Disease Progressive Neuroimaging Initiative (PDPNI) is a longitudinal observational clinical study. In PDPNI, the clinical and imaging data of patients diagnosed with Parkinsonian syndromes and Idiopathic rapid eye movement sleep behavior disorder (RBD) were longitudinally followed every two years, aiming to identify progression biomarkers of Parkinsonian syndromes through functional imaging modalities including FDG-PET, DAT-PET imaging, ASL MRI, and fMRI, as well as the treatment conditions, clinical symptoms, and clinical assessment results of patients. From February 2012 to March 2019, 224 subjects (including 48 healthy subjects and 176 patients with confirmed PDS) have been enrolled in PDPNI. The detailed clinical information and clinical assessment scores of all subjects were collected by neurologists from Huashan Hospital, Fudan University. All subjects enrolled in PDPNI were scanned with <superscript>18</superscript> F-FDG PET, <superscript>11</superscript> C-CFT PET, and MRI scan sequence. All data were collected in strict accordance with standardized data collection protocols.<br />Competing Interests: All the contributing authors declare no conflict of interest.<br /> (Copyright © 2021 Shiyi Zhu et al.)